Ventrogluteal Injection Technique for Testosterone
Preferred Injection Site and Rationale
For self-administered testosterone cypionate or enanthate injections, inject into the vastus lateralis (anterolateral thigh) muscle; when another person administers the injection, the ventrogluteal site is acceptable. 1, 2
The ventrogluteal site is increasingly recommended in clinical literature because it is farther from major neurovascular structures than the dorsogluteal site—specifically, the ventrogluteal site maintains an average distance of 13.87 mm from the superior gluteal artery and 11.82 mm from the superior gluteal nerve, compared to only 6.83 mm and 5.67 mm respectively at the dorsogluteal site. 3 However, the FDA-approved label for testosterone cypionate explicitly states "intramuscular injections should be given deep in the gluteal muscle," without specifying ventrogluteal versus dorsogluteal. 4
Anatomic Identification of the Ventrogluteal Site
Use the G (geometric) method rather than the traditional V method for site identification, as it is significantly more reliable for successful intramuscular injection. 5
G Method Landmarks:
- Place the palm of your hand on the greater trochanter of the femur (the bony prominence on the lateral hip). 5
- Point your fingers toward the anterior superior iliac spine. 5
- The injection site is the center of the triangle formed by your index finger, middle finger, and the iliac crest. 5
The G method achieves successful intramuscular injection in 75% of patients versus only 57% with the V method, and reduces the risk of bone injury. 5
Needle Selection by Patient Characteristics
Needle length must be individualized based on sex, BMI, and body composition to ensure intramuscular rather than subcutaneous deposition. 5, 6
Males:
- Use a 32 mm (1.25 inch) needle for all males at the ventrogluteal site; this achieves successful intramuscular injection in 92% of men. 5, 6
Females:
- Use a 38 mm (1.5 inch) needle for all females at the ventrogluteal site to avoid subcutaneous injection. 6
- For females with BMI <23 kg/m² or weight <60 kg, use a shorter needle (32 mm) to avoid bone injury. 5
- For females with BMI >30 kg/m² or hip circumference >90 cm, a 38 mm needle is mandatory to penetrate thicker subcutaneous fat (average 16% risk of bone injury and 25% risk of subcutaneous injection even with the G method). 5
Even with optimal technique, only 59% of females achieve successful intramuscular injection at the ventrogluteal site using standard needles, compared to 92% of males. 5
Injection Technique
- Clean the site with alcohol and allow it to dry completely. 7
- Insert the needle at a 90-degree angle to the skin surface using a dart-like motion. 7
- Aspirate briefly (though current evidence questions the necessity of aspiration for intramuscular injections in the gluteal region). 7
- Inject the testosterone slowly (over 30–60 seconds for a 1 mL volume) to minimize pain and tissue trauma. 7
- Withdraw the needle and apply gentle pressure; do not massage the site. 7
Dosing and Monitoring
Administer 100 mg (0.5 mL of 200 mg/mL testosterone cypionate) intramuscularly once weekly; this regimen provides more stable serum testosterone levels than the traditional 200 mg every two weeks. 1, 8
- Measure serum testosterone at 3–6 months, targeting 400–700 ng/dL; for weekly injections, draw blood mid-interval (day 3–4 after dose) rather than at trough. 1, 9
- Check hematocrit at baseline, 3–6 months, and annually; discontinue immediately if hematocrit exceeds 54%. 1, 2
- For men ≥40 years, obtain baseline PSA and digital rectal exam, repeat PSA at 3–6 months and annually, and refer to urology if PSA rises >1.4 ng/mL within 12 months. 1, 2
Critical Safety Considerations
Testosterone undecanoate (long-acting 750 mg formulation) must never be injected at the ventrogluteal site or any site other than the deep dorsogluteal muscle, due to the risk of pulmonary oil microembolism. 2 This restriction applies only to testosterone undecanoate; testosterone cypionate and enanthate may be safely administered at the ventrogluteal site. 2
Common Pitfalls to Avoid
- Do not use the ventrogluteal site in obese patients (BMI >30 kg/m²) or those with endomorph body habitus without a 38 mm needle, as subcutaneous injection is highly likely. 6
- Do not use the dorsogluteal site when the ventrogluteal site is available, as the dorsogluteal site has significantly shorter distances to the superior gluteal artery and nerve (approximately half the safety margin). 3
- Do not rely on the traditional V method for site identification; the G method is objectively superior and reduces the risk of both bone injury and subcutaneous injection. 5